EMA Prepares To Re-Start ‘Updated’ Clinical Data Publication Policy

The European Medicines Agency has issued revised guidance on its Clinical Data Publication policy to help companies navigate procedural changes that will be introduced when the publication of clinical trial data on non-COVID-19 products is partially resumed under the policy from September 2023.

Clinical trial
Clinical Trial Transparency Can Help Avoid Duplicate Studies And Foster Innovation • Source: Alamy

The European Medicines Agency has updated the Q&A document on how companies should go about identifying, redacting, anonymizing and submitting clinical trial documents ahead of the phased re-start of its landmark transparency policy in September. 

The Q&As have been revised to clarify the scope of the Clinical Data Publication (CDP) policy, and address procedural changes...

More from Europe

More from Geography

EU Fines Alchem Over Buscopan API Cartel

 
• By 

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

Bayesian Statistics In EU Clinical Trials: EMA Discusses Balancing Efficiency With Rigor

 

Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.

Korea Pre-Review Consultations Help Accelerate R&D

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.